ANTEOTECH LTD — Investor Presentation 2011

May 25, 2011

==> picture [290 x 147] intentionally omitted <==

Southern Cross Equities Life Sciences Conference Anteo Diagnostics (ASX:ADO) Better Binding - Faster Dr. Geoff Cumming - CEO May 2011

Disclaimer

The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

An y forward lookin g statements in this p resentation have been p re p ared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results

could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

==> picture [176 x 89] intentionally omitted <==

Mix&Go™– A Game Changing Technology

• ADO has developed Mix&Go™– a molecular ‘glue’ that significantly improves pathology tests

• Mix&Go™is proven and already licensed to two major healthcare companies – Bangs Laboratories and Merck

• Immunoassay tests using Mix&Go™ now rival molecular tests – immuno convenience with molecular sensitivity

• Mix&Go™technology results in earlier detection of disease (more treatment options) OR less expensive test manufacture (less antibody used)

• Potential to access numerous and large healthcare segments – pathology (IVD), research,

• point of care diagnostics, immunoprecipitation

• Mix&Go™has a solid pipeline of opportunity – over 60 global healthcare companies are

• currently assessing Mix&Go™in-house for use/licensing

• ADO is targeting the large and proven IVD market with Mix&Go™- ~$10 billion p.a. Immunoassays sector; plus now ~$2.4 billion p.a molecular biology sector

• IVD market is highly competitive - controlled by seven majors and a number of mid tier operators – who actively search for technologies like Mix&Go™to capture market share

Company Overview

Strong Leadership:

Management has a solid track record of developing commercially successful products

Business Model :

Revenues from product sales and royalties with diagnostic and other life sciences companies.

Proven Technology Platform:

Proprietary technology licensed to major international players with additional deals anticipated

Patented Technology: Robust Deal Portfolio:

Strong Balance Sheet:

Significant and growing patent portfolio

Over 60 of the major global names in several distinct markets and market segments are actively assessing our process in-house $7.0 million of cash gives us runway to end of calendar 2013 on current burn rate

==> picture [176 x 89] intentionally omitted <==

Lead Product: Mix&Go[TM]

• Mix&Go™is a molecular glue – diagnostics, drug manufacturing and drug discovery all benefit from “improved” surface properties – it enables better and earlier disease detection

• -

• Mix&Go™is a novel ‘glue’ like a two sided velcro

• Result of screen on 8000 surfaces to find “glue” to bind antibodies to a solid surface

• Successfully trialled by all major bead manufacturers and found to be faster , easier and less variable than current practice to bind proteins to beads

• Successfully trialled by most major IVD suppliers and found to improve sensitivity of tests, where there is a clinical benefit; be easier than current practice and lead to significant reductions in COGS

• IVD suppliers do not change easily – look for points of differentiation, which are often small - Mix&Go™provides many fold improvements

==> picture [186 x 94] intentionally omitted <==

Mix&Go[TM] Technology

Without Mix&Go™the signal is weak and/or variable. Without Mix&Go[TM ]

==> picture [515 x 69] intentionally omitted <==

----- Start of picture text -----

2xSignal 2xSignal No Signal
1xSignal
----- End of picture text -----

==> picture [576 x 33] intentionally omitted <==

With Mix&Go[TM]

==> picture [626 x 183] intentionally omitted <==

----- Start of picture text -----

4xSignal 4xSignal 4xSignal 4xSignal
:
Impact of Mix&Go [TM]
= detect disease earlier = more treatment options
----- End of picture text -----

Why is Mix&Go[TM] a Game Changer?

Sensitivity is the key

Mix & Go enables 10x more sensitive test than existing immunoassays - better sensitivity means earlier detection of disease.

A whole new market for high-sensitivity testing awaits with Mix&Go[TM]

Due to sensitivity limitations, only 2,000 serum proteins are routinely analysed. There are about 100,0000 serum proteins believed to exist in human blood which are not analysed due to limitations in existing assays - Mix & Go removes these limitations Speed to market for new tests being developed

Customers comment that it reatl sim lifies and s eeds u R&D activities – therefore g y p p p ability to get products to market quicker.

Ease of manufacture

A one step procedure and robust to changes in other variables.

Less raw materials required to produce existing high volume tests

Demonstrated as much as 80% saving in key component (antibodies) in partnership with IVD company.

Scalability

Shown 20,000x change in scale without any changes to procedures.

==> picture [129 x 65] intentionally omitted <==

ADO is now building multiple pipeline and licensing opportunities for Mix&Go™

			TESTING
	SECTOR	MARKET PARTICIPANTS	MIX&GO™IN
			HOUSE
IVD (Pathology)		Bead manufacturers (Dynal, Merck, Bangs, Seradyn)	√√√√
		Test manufacturers/suppliers (Roche, Beckman, Abbott, Dia Sorin, Ortho, bioMerieux)	√√√
Healthcare Research		Membrane manufacturers (Pall, Millipore)	√√
Point of Care		Test manufacturers/suppliers (Alere)	√√
Molecular Diagnostics		Instrument manufacturers (Life Technologies)	√
Immunoprecipitation		Proteomics manufacturers/suppliers (GE Healthcare)	√√√
	ADO is currently	pursuing opportunities in all these sectors with nearly 60
		healthcare companies

Mix&Go[TM] - Commercialisation Strategy

• ADO has licensed Bangs Laboratories to use Mix&Go[TM ] on “approved” Bangs manufactured beads – currently two products including its largest selling product

• Revenue from sale of Mix&Go[TM ] and royalty on sale of Mix&Go[TM ] treated product

• Signed Agreement with Merck Chimie for Anteo to manufacture two new products for them to package and sell

• Strategic intent to access research market through bead manufacturers

• Strategic intent to access pathology market through IVD manufacturers/suppliers

• Model to be replicated in POC market segment and immunoprecipitation market

==> picture [223 x 112] intentionally omitted <==

What could Mix&Go[TM ] be worth? Realistically Accessible Market for ADO

• Research Market $5-$10M

• IVD Market $30-$150M

• POC Market $50-$250M

• Molecular Diagnostics >$100M

• Immunoprecipitation >$100M

==> picture [176 x 89] intentionally omitted <==

$600 million market opportunity for ADO

Other Mix&Go™Applications

• Other (non-human) diagnostic markets – including veterinary and agriculture

• Other diagnostic platforms – including biosensors and biochips

• Verify product authenticity e.g. LVMH, Bank Notes

• Marine anti - fouling – attach biocide to exposed surfaces

• Artificial cartilage on prostheses

• Tracking and other data collection for logistics purposes

• Solar cell production

==> picture [223 x 112] intentionally omitted <==

Short term value drivers

Research & Development:

Currently 2-3 healthcare R&D companies actively considering Mix&Go™ - short term revenue opportunities as R&D companies take less time on approval processes

Major global IVD Players:

ADO is currently working on supply agreements with leading global IVD players

Life sciences market:

ADO actively pursuing possible supply agreement with leading global life sciences company

Value will come from Mix&Go™ enabling greater sensitivity and ease of develo ment and roduction – o ens u a whole new market for testin p p p p g

==> picture [169 x 85] intentionally omitted <==

Recent Developments

• Bangs launch 2nd product using Mix&Go™ Feb 2011:

• Confirms market acceptance of technology gaining traction

• $5.9m raised through the exercise of options at 6.5 and 5.5 cents Feb and April 2011 :

• 97% of 96.2m options were exercised – 3 years runway

• European Patent Office confirms intention to grant the ‘Generation of Surface Coating Diversity’ patent for Mix&Go™ March 2011:

• Means the patent will shortly be granted to protect the IP that led to the discovery of Mix&Go™

• Ms. Sandra (Sam) Andersen appointed as Non-Executive Director May 2011 :

• 6 month share price (As at 19 May 2011)

==> picture [223 x 112] intentionally omitted <==

==> picture [312 x 203] intentionally omitted <==

Corporate Structure & Financials

Share Price (52 Week Range): 4 cents to 10.5 cents Currently around 8.5 cents

Net Cash Position: $7,000,000

Market Capitalization: $65 million

Shareholders: 3,360

Average Daily Volume: 15,451,033

Top 20: Hold 41.15% issued capital

Shares on Issue (fully diluted): 761,951,591

Directors/Staff: 17.8%

==> picture [223 x 112] intentionally omitted <==

ANTEO DIAGNOSTICS LTD Top 20 Holdings as at 20 May 2011

	Shareholder Name	Shares	Shareholder Name	Shares
	First Cape Management PTY LTD	77,511,398	Mr Thomas David Cumming	11,000,000
	Austcorp No 190 Pty Ltd	32,889,866	HSBC Custody Nominees (Australia)	11,000,000
	Nimrod Finance LTD	19,867,574	ACT 2 PTY LTD	10,000,000
	Mr Ian Andrew Noble & Mrs Annette Joy Noble	16,500,000	Sietsma Holdings PTY LTD	10,000,00
	LYC C ti Pt Ltd orpora on y	16 448 000 , ,	M li PTY LTD asa	9 000 000 , ,
	Transocean Securities PTY LTD	16,255,121	Mr Konstantinos Bagiartakis	8,035,755
	Mr Stephen Charles O’Halloran	15,030,000	Mr Janakan Krishnarajah	6,536,000
	Comsec Nominees PTY LTD	13,327,406	HUB24 Nominees PTY LTD	6,000,000
	Tisia Nominees PTY LTD	12,224,785	Welas PTY LTD	5,500,000
	Miss Wei Wei Wai	11,800,000	Mr. Nobuyoshi Maeji	4,815,781

Summary

• Mix&Go™is a proven and commercialised technology

• Mix&Go™now targeting an established IVD (pathology) market

• Mix&Go™being tested by healthcare companies in multiple sectors - pathology (IVD), research, point of care, diagnostics, immunoprecipitation, R&D

• Over 60 leading healthcare companies currently testing and assessing the technology – not one has said no

• Mix&Go™has multiple applications outside of healthcare

• ADO well funded with $7.0 million in cash – potential to access current market opportunities with current cash position

==> picture [223 x 112] intentionally omitted <==

Contact

Dr. Geoff Cumming Chief Executive Officer Anteo Diagnostics Limited Tel: +61 2 8823 3110

==> picture [721 x 270] intentionally omitted <==